Business
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be presented IRVINE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address patient needs, starting with eye care, through the application of proven science and new technology, today announced that additional efficacy results from the Saturn-2 pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming American Academy of Optometry 2022 Annual Meeting in San Diego, California. Additionally, data from an investigator-initiated study evaluating a potential correlation between meibomian gland atrophy and collarettes, the pathognomonic sign of Demodex blepharitis, will be presented. “We are encouraged by the strong and consistent data from our Saturn-2 pivotal Phase 3 trial, which further demonstrates the potential of TP-03, if approved, in treating Demodex blepharitis,” said José Trevejo, M.D., Ph.D., Chief Medical Officer of Tarsus. “Additionally, new research studying a potential correlation between Demodex blepharitis and meibomian gland atrophy underscores the importance of Demodex as a contributing factor to meibomian gland disease.” Tarsus recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TP-03 based on the Saturn-1 and Saturn-2 pivotal trial results, both of which met the primary endpoint and all secondary endpoints, as well as additional studies. There are currently no FDA-approved treatments for Demodex blepharitis. The posters being presented at the meeting are listed below: Safety & Efficacy of Lotilaner Ophthalmic Solution, 0.25% in Treating Demodex Blepharitis Results of the Phase III Saturn-2 Trial; Paul Karpecki, O.D., et al. Date: Thursday, October 27, 2022, 4:30-6:30 p.m. PTLocation: Poster Board #35 Meibomian Gland Atrophy in Patients with Demodex Blepharitis; Cecelia Koetting, O.D., Elizabeth Yeu, M.D. Date: Friday, October 28, 2022, 1:00-3:00 p.m. PTLocation: Poster Board #124 Tarsus’ Chief Commercial Officer, Aziz Mottiwala, will also participate in the American Academy...